Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy

Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy

Sipuleucel-T (Provenge) is the first live cell vaccine approved for advanced, hormonally refractive prostate cancer. However, survival benefit is modest and the optimal combination or schedule of sipuleucel-T with androgen depletion remains unknown. We employ a nonlinear dynamical systems approach t...

Full description

Bibliographic Details
Main Authors: Harsh Vardhan Jain, Inmaculada C. Sorribes, Samuel K. Handelman, Johnna Barnaby, Trachette L. Jackson
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
ADT
immunotherapy
mathematical model
prostate cancer
provenge
standing variations
Online Access:https://www.mdpi.com/2072-6694/13/8/1872

Internet

https://www.mdpi.com/2072-6694/13/8/1872

Similar Items